Q3 2022 13F Holders as of 30 Sep 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share (the "Common Stock")
-
Shares outstanding
-
62,650,155
-
Total 13F shares
-
44,958,338
-
Share change
-
-65,848
-
Total reported value
-
$1,760,616,708
-
Put/Call ratio
-
23%
-
Price per share
-
$39.16
-
Number of holders
-
177
-
Value change
-
+$7,132,722
-
Number of buys
-
79
-
Number of sells
-
86
Institutional Holders of Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) as of Q3 2022
As of 30 Sep 2022,
Sage Therapeutics, Inc. - Common Stock, par value $0.0001 per share (the "Common Stock") (SAGE) was held by
177 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
44,958,338 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., VANGUARD GROUP INC, Bellevue Group AG, STATE STREET CORP, PRICE T ROWE ASSOCIATES INC /MD/, JPMORGAN CHASE & CO, GOLDMAN SACHS GROUP INC, BOXER CAPITAL, LLC, and AMERIPRISE FINANCIAL INC.
This page lists
179
institutional shareholders reporting positions in this security
for the Q3 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.